Summary of Study ST002941

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001830. The data can be accessed directly via it's Project DOI: 10.21228/M85H91 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST002941
Study TitleTargeted analyses of microbial metabolites of xanthohumol
Study SummaryThe Xanthohumol microbiome and signature (XMaS) study in healthy adults was a phase I, triple-masked, placebo-controlled clinical trial in healthy adults investigating effects of a natural product supplement of gut microbiome composition and metabolism. Xanthohumol, a flavonoid from the hops plant or placebo was administered to 27 healthy adults daily for eight weeks. Fecal, plasma, and 24-hr urine collections were obtained from participants at baseline and 2-week intervals. The aim of this study was to quantify major microbial metabolites of xanthohumol.
Institute
Oregon State University
Last NameJamieson
First NamePaige
Address307 LINUS PAULING SCIENCE CTR
Emailjamiesop@oregonstate.edu
Phone5417379804
Submit Date2023-10-22
Num Groups2
Total Subjects27
Analysis Type DetailLC-MS
Release Date2024-01-01
Release Version1
Paige Jamieson Paige Jamieson
https://dx.doi.org/10.21228/M85H91
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001830
Project DOI:doi: 10.21228/M85H91
Project Title:Targeted analyses of microbial metabolism for the XMaS clinical trial
Project Summary:The Xanthohumol microbiome and signature (XMaS) study in healthy adults was a phase I, triple-masked, placebo-controlled clinical trial in healthy adults investigating effects of a natural product supplement of gut microbiome composition and metabolism. Xanthohumol, a flavonoid from the hops plant or placebo was administered to 27 healthy adults daily for eight weeks. Fecal, plasma, and 24-hr urine collections were obtained from participants at baseline and 2-week intervals. The main objective was to examine clinical safety and subjective tolerability of xanthohumol compared to placebo. Additional aims were to monitor biomarkers of inflammation, gut permeability, bile acid metabolism, short-chain fatty acids, and metabolism of xanthohumol.
Institute:Oregon State University
Last Name:Jamieson
First Name:Paige
Address:307 LINUS PAULING SCIENCE CTR
Email:jamiesop@oregonstate.edu
Phone:5417379804

Subject:

Subject ID:SU003054
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id time_weeks intervention
SA319970s106-10 control
SA319971s112-10 control
SA319972s117-10 control
SA319973s122-10 control
SA319974s104-10 control
SA319975s126-10 control
SA319976s109-10 control
SA319977s110-10 control
SA319978s107-10 control
SA319979s114-10 control
SA319980s121-10 control
SA319981s118-10 control
SA319982s119-10 control
SA319983s101-10 treated
SA319984s111-10 treated
SA319985s131-10 treated
SA319986s102-10 treated
SA319987s123-10 treated
SA319988s124-10 treated
SA319989s116-10 treated
SA319990s130-10 treated
SA319991s127-10 treated
SA319992s115-10 treated
SA319993s103-10 treated
SA319994s113-10 treated
SA319995s129-10 treated
SA319996s105-10 treated
SA319997s121-22 control
SA319998s114-22 control
SA319999s117-22 control
SA320000s110-22 control
SA320001s119-22 control
SA320002s118-22 control
SA320003s112-22 control
SA320004s122-22 control
SA320005s109-22 control
SA320006s104-22 control
SA320007s106-22 control
SA320008s107-22 control
SA320009s126-22 control
SA320010s113-22 treated
SA320011s124-22 treated
SA320012s127-22 treated
SA320013s131-22 treated
SA320014s105-22 treated
SA320015s116-22 treated
SA320016s103-22 treated
SA320017s101-22 treated
SA320018s123-22 treated
SA320019s130-22 treated
SA320020s102-22 treated
SA320021s129-22 treated
SA320022s111-22 treated
SA320023s115-22 treated
SA320024s118-34 control
SA320025s119-34 control
SA320026s114-34 control
SA320027s112-34 control
SA320028s110-34 control
SA320029s107-34 control
SA320030s117-34 control
SA320031s122-34 control
SA320032s106-34 control
SA320033s109-34 control
SA320034s104-34 control
SA320035s121-34 control
SA320036s126-34 control
SA320037s131-34 treated
SA320038s127-34 treated
SA320039s123-34 treated
SA320040s124-34 treated
SA320041s129-34 treated
SA320042s130-34 treated
SA320043s115-34 treated
SA320044s113-34 treated
SA320045s111-34 treated
SA320046s105-34 treated
SA320047s103-34 treated
SA320048s101-34 treated
SA320049s116-34 treated
SA320050s102-34 treated
SA320051s112-46 control
SA320052s121-46 control
SA320053s122-46 control
SA320054s126-46 control
SA320055s104-46 control
SA320056s106-46 control
SA320057s107-46 control
SA320058s110-46 control
SA320059s109-46 control
SA320060s118-46 control
SA320061s117-46 control
SA320062s114-46 control
SA320063s119-46 control
SA320064s127-46 treated
SA320065s103-46 treated
SA320066s129-46 treated
SA320067s124-46 treated
SA320068s131-46 treated
SA320069s105-46 treated
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 135

Collection:

Collection ID:CO003047
Collection Summary:Fecal samples were collected longitudinally at 2-week intervals during the 8-week study. Samples were kept on ice immediately after collection and snap-frozen, then stored in -80 freezers until processing.
Sample Type:Feces

Treatment:

Treatment ID:TR003063
Treatment Summary:Participants were randomly allocated to intervention arms to receive either 24 mg or a rice protein placebo capsule daily for 8 weeks. Clinic check-in and sample collections occurred at baseline and 2-week intervals until study close-out (week 8).

Sample Preparation:

Sampleprep ID:SP003060
Sampleprep Summary:Fecal samples were dried using vacuum desiccator and 70% methanol:water (1:4 w/v) was added for fecal homogenate. Samples were centrifuged and supernatant was collected. Metabolites were extracted with MTBE (3x with 200 uL) and organic layers were combined and evaporated under gentle nitrogen stream before reconstitution in 100 uL 50% methanol:water.

Combined analysis:

Analysis ID AN004826
Analysis type MS
Chromatography type Reversed phase
Chromatography system Shimadzu LC
Column Agilent ZORBAX 300SB C8 reversed phase column (2.1 x 50 mm, 3.5 µm)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name ABI Sciex 4000 QTrap
Ion Mode NEGATIVE
Units ng/g

Chromatography:

Chromatography ID:CH003646
Instrument Name:Shimadzu LC
Column Name:Agilent ZORBAX 300SB C8 reversed phase column (2.1 x 50 mm, 3.5 µm)
Column Temperature:40
Flow Gradient:from 0 to 0.5 min, 5% B; from 0.5 to 3 min, B increased to 100%; for 1 min, B was held at 100%; and following the column was allowed to re-equilibrate at 5% B for 2 min
Flow Rate:0.4 mL/min
Solvent A:water with 0.1% formic acid (v/v)
Solvent B:acetonitrile with 0.1% formic acid (v/v)
Chromatography Type:Reversed phase

MS:

MS ID:MS004572
Analysis ID:AN004826
Instrument Name:ABI Sciex 4000 QTrap
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:All metabolites were verified by matching m/z value, retention times, and product ions of SRM transitions with those of authenticated standards.
Ion Mode:NEGATIVE
  logo